Answers are grounded in this paper and cite their sources.
In patients at high risk for device-related thrombus after left atrial appendage closure, antithrombotic drug selection based on CYP2C19 loss-of-function polymorphisms should be considered.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: